No Data
Hanshang Group's semi-annual report for 2024.
Hanshang Group's 2024 semi-annual report summary.
Hanshang Group (600774.SH): net income in the first half of the year was 8.5108 million yuan, a year-on-year decrease of 82.35%.
Hanshang Group (600774.SH) released its semi-annual report for 2024, with operating income of 626 million yuan, a 10.74% year-on-year decrease; net income attributable to shareholders of listed companies was 8.5108 million yuan, a YoY decrease of 82.35%; net income attributable to shareholders of listed companies after deducting non-recurring gains and losses was -4.0843 million yuan; basic earnings per share was 0.0288 yuan. The main factors affecting performance are: the impact of subsidiary Dikang Pharmaceutical on group procurement and rising prices of medicinal materials, which led to a decrease in profits; subsidiary Dikang Traditional Chinese Medicine Pharmaceutical resumed work and production this year.
Hanshang Group (600774.SH), some directors, supervisors, executives, and management personnel have collectively increased their shareholding by 0.7442 million shares.
Hanshang Group (600774.SH) announced that as of the disclosure date of the announcement, some directors, supervisors, and management personnel of the company...
Hanshang Group (600774.SH): The controlling shareholder has cumulatively increased its shareholding by 1.00%. The shareholding plan has been completed.
Hanshang Group (600774.SH) announced that its controlling shareholder, Zhuoer Holdings, accumulated a shareholding of 2.9504 million shares of the company's stock through the Shanghai Stock Exchange trading system via centralized bidding trading from April 29, 2024 to July 16, 2024, holding 1.00% of the company's issued shares, with an accumulated shareholding amount of 21.4928 million yuan. The shareholding plan has been fully implemented.
A-share anomaly | hanshang group fell more than 8%, medicinal material prices rose, and the net profit in the middle period is expected to decline by more than 80%.
On July 15th, Gelunhui reported that Hanshang Group (600774.SH) fell more than 8%, hitting a new 2-month low at 7.18 yuan, with a total market value of 2.12 billion yuan. The company issued a pre-reduction announcement yesterday evening, expecting that the net income for the first half of the year will be around 8 million yuan, a year-on-year decrease of about 83.41%. During the reporting period, the company's subsidiary, Chengdu Dikang Pharmaceutical Co., Ltd. was affected by factors such as group procurement and rising prices of medicinal materials, resulting in reduced profits.
No Data
No Data